Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Eli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer

Author: Vandana Singh | February 03, 2021 06:24am

Eli Lilly and Company (NYSE: LLY) and its collaborating partner Innovent Biologics Inc (OTC:IVBXF) has announced that the National Medical Products Administration (NMPA) of China has approved the supplemental marketing application seeking approval for TYVYT (sintilimab injection) in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with nonsquamous non-small cell lung cancer.
This is the second approved indication of TYVYT in China, following the first approved indication by the NMPA in December 2018 to treat relapsed or refractory classical Hodgkin's lymphoma after at least two lines of systemic chemotherapy.
Price Action: LLY shares closed 2.75% lower at $197.56 on Tuesday.

Posted In: IVBXF LLY